Biology of Blood and Marrow Transplantation
Volume 13, Issue 7 , Pages 790-805 , July 2007

Impact of Postgrafting Immunosuppressive Regimens on Nonrelapse Mortality and Survival after Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant Using the Fludarabine and Low-Dose Total-Body Irradiation 200-cGy

  • Liang-Piu Koh

      Affiliations

    • Bone Marrow Transplant Program, Department of Haematology, Singapore General Hospital, Singapore
    • Stem Cell Transplant Program, Department of Hematology-Oncology, National University Hospital, Singapore
    • Corresponding Author InformationCorrespondence and reprint requests: Liang-Piu Koh, MD, Stem Cell Transplant Program, Department of Hematology-Oncology, National University Hospital, Singapore.
    • ,
  • Chien-Shing Chen

      Affiliations

    • Stem Cell Transplant Program, Department of Hematology-Oncology, National University Hospital, Singapore
    • Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
    • ,
  • Bee-Choo Tai

      Affiliations

    • Centre for Molecular Epidemiology, and Department of Community, Occupation and Family Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
    • ,
  • William Y.K. Hwang

      Affiliations

    • Bone Marrow Transplant Program, Department of Haematology, Singapore General Hospital, Singapore
    • ,
  • Lip-Kun Tan

      Affiliations

    • Stem Cell Transplant Program, Department of Hematology-Oncology, National University Hospital, Singapore
    • ,
  • Hong-Yen Ng

      Affiliations

    • Department of Pharmacy, Singapore General Hospital, Singapore
    • ,
  • Yeh-Ching Linn

      Affiliations

    • Bone Marrow Transplant Program, Department of Haematology, Singapore General Hospital, Singapore
    • ,
  • Mickey B.C. Koh

      Affiliations

    • Bone Marrow Transplant Program, Department of Haematology, Singapore General Hospital, Singapore
    • ,
  • Yeow-Tee Goh

      Affiliations

    • Bone Marrow Transplant Program, Department of Haematology, Singapore General Hospital, Singapore
    • ,
  • Belinda Tan

      Affiliations

    • Stem Cell Transplant Program, Department of Hematology-Oncology, National University Hospital, Singapore
    • ,
  • Shan Lim

      Affiliations

    • Stem Cell Transplant Program, Department of Hematology-Oncology, National University Hospital, Singapore
    • ,
  • Yee-Mei Lee

      Affiliations

    • Stem Cell Transplant Program, Department of Hematology-Oncology, National University Hospital, Singapore
    • ,
  • Kar-Wai Tan

      Affiliations

    • Department of Pharmacy, Singapore General Hospital, Singapore
    • ,
  • Te-Chih Liu

      Affiliations

    • Stem Cell Transplant Program, Department of Hematology-Oncology, National University Hospital, Singapore
    • ,
  • Heng-Joo Ng

      Affiliations

    • Bone Marrow Transplant Program, Department of Haematology, Singapore General Hospital, Singapore
    • ,
  • Yvonne S.M. Loh

      Affiliations

    • Bone Marrow Transplant Program, Department of Haematology, Singapore General Hospital, Singapore
    • ,
  • Benjamin M.F. Mow

      Affiliations

    • Stem Cell Transplant Program, Department of Hematology-Oncology, National University Hospital, Singapore
    • ,
  • Daryl C.L. Tan

      Affiliations

    • Bone Marrow Transplant Program, Department of Haematology, Singapore General Hospital, Singapore
    • ,
  • Patrick H.C. Tan

      Affiliations

    • Haematology and Stem Cell Transplant Center, Mount Elizabeth Hospital, Singapore

Received 5 November 2006 ,Accepted 1 March 2007.

References 

  1. Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97:631–637
  2. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756–763
  3. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390–3400
  4. Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 2003;101:1620–1629
  5. Maris MB, Sandmaier BM, Storer BE, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood. 2004;104:3535–3542
  6. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003;102:756–762
  7. Mielcarek M, Burroughs L, Leisenring W, et al. Prognostic relevance of “early-onset” graft-versus-host disease following non-myeloablative haematopoietic cell transplantation. Br J Haematol. 2005;129:381–391
  8. Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol. 2005;23:1993–2003
  9. Kottaridis PD, Milligan D, Chopra R, et al. In vivo CAMPATH-IH prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000;96:2419–2425
  10. Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood. 2004;104:3865–3871
  11. Ho AY, Pagliuca A, Kenyon M, et al. Reduced intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood. 2004;104:1616–1623
  12. Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft versus Hodgkin’s lymphoma effect after reduced intensity allogeneic transplantation. Lancet. 2005;365:1934–1941
  13. Faulkner R, Craddock C, Byrne J, et al. BEAM-alemtuzumab reduced intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood. 2004;103:428–434
  14. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300:1068–1073
  15. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–562
  16. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med. 1981;304:1529–1533
  17. Slavin S, Weiss L, Morecki S, Weigensberg M. Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation. Cancer Immunother. 1981;11:155–158
  18. Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 1997;89:3048–3054
  19. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft versus leukemia without myeloablative therapy. Blood. 1997;89:4531–4536
  20. Kroger N, Shaw B, Iacobelli S, et al. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol. 2005;129:631–643
  21. Crawley C, Lalancette M, Szydlo R, et al. Outcomes for reduced intensity allogeneic transplantation for multiple myeloma; an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood. 2005;105:4532–4539
  22. Perez-Simon JA, Kottaridis PD, Martino R, et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood. 2002;100:3121–3127
  23. Crawley C, Szydlo R, Lalancette M, et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood. 2005;106:2969–2976
  24. Ramsay NKC, Kersey JH, Robison LL, et al. A randomized study of the prevention of acute graft-versus-host disease. N Engl J Med. 1982;306:392–397
  25. Storb R, Deeg HJ, Pepe M, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood. 1989;73:1729–1734
  26. Storb R, Deeg HJ, Pepe M, et al. Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. Br J Haematol. 1989;72:567–572
  27. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;20(314):729–735
  28. Chao NJ, Schmidt GM, Niland JC, et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med. 1993;329:1225–1230
  29. Deeg HJ, Lin D, Leisenring W, et al. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. Blood. 1997;89:3880–3887
  30. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host-disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998;92:2303–2314
  31. Ruutu T, Volin L, Parkkali T, et al. Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study. Blood. 2000;96:2391–2398
  32. Locatelli F, Bruno B, Zecca M, et al. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood. 2000;96:1690–1697
  33. Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 2000;96:2062–2068
  34. Srinivasan R, Geller N, Chakrabarti S, et al. Evaluation of three different cyclosporine-based graft versus host disease (GVHD) prophylaxis regimens following nonmyeloablative hematopoietic stem cell transplantation (NST) [abstract 1236]. Blood. 2004;104(Supp 1):349a
  35. Chao NJ, Snyder DS, Jain M, et al. Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. Biol Blood Marrow Transplant. 2000;6:254–261
  36. Sandmaier BM, Maris M, Maloney DG, et al. Low-dose total body irradiation (TBI)conditioning for hematopoietic cell transplantation (HCT) from HLA-matched related (MRD) and unrelated (URD) donors for patients with hematologic malignancies: a 5 year experience [abstract 264]. Blood. 2003;102(Suppl 1):78a–79a
  37. Ugozzoli L, Yam P, Petz LD, et al. Amplification by the polymerase chain reaction of hypervariable regions of the human genome for evaluation of chimerism after bone marrow transplantation. Blood. 1991;77:1607–1615
  38. Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–828
  39. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28:250–259
  40. Common terminology criteria for adverse events. Available at: http://ctep.cancer.gov/reporting/ctc.html.
  41. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants (Part I: unadjusted analysis). Bone Marrow Transplant. 2001;28:909–915
  42. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants (Part 2: Regression modeling). Bone Marrow Transplant. 2001;28:1001–1011
  43. Tai BC, Machin D, White I, Gebski V European Osteosarcoma Intergroup. Competing risks analysis of patients with osteosarcoma: a comparison of four different approaches. Stat Med. 2001;20:661–684
  44. Craddock C, Szydlo RM, Klein JP, et al. Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission. Blood. 2000;96:86–90
  45. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  46. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–170
  47. Junghanss C, Boeckh M, Carter RA, et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood. 2002;99:1978–1985
  48. Nash RA, Pepe MS, Storb R, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood. 1992;80:1838–1845
  49. Storb R, Prentice RL, Buckner CD, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings (Beneficial effect of a protective environment). N Engl J Med. 1983;308:302–307
  50. Oh H, Loberiza FR, Zhang MJ, et al. Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood. 2005;105:1408–1416
  51. Lin MT, Storer B, Martin PJ, et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med. 2003;349:2201–2210
  52. de Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004;104:865–872
  53. Hegenbart U, Niederwieser D, Sandmaier BM, et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol. 2006;24:444–453
  54. Bethge WA, Storer BE, Maris MB, et al. Relapse or progression after hematopoietic cell transplantation using nonmyeloablative conditioning: effect of interventions on outcome. Exp Hematol. 2003;31:974–980
  55. van Besien K, Artz A, Smith S, et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23:5728–5738
  56. Alyea EP, Kim HT, Ho V, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood. 2005;105:1810–1814
  57. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003;102:2021–2030
  58. Sloand E, Childs RW, Solomon S, et al. The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia. Bone Marrow Transplant. 2003;32:897–901
  59. Michallet M, Bilger K, Garban F, et al. Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome. J Clin Oncol. 2001;19:3340–3349
  60. Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood. 2002;100:4310–4316
  61. Koh LP, Koh MB, Ng HY, et al. Allogeneic hematopoietic stem cell transplantation for patients with severe aplastic anemia following nonmyeloablative conditioning using 200-cGy total body irradiation and fludarabine. Biol Blood Marrow Transplant. 2006;12:887–890
  62. Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol. 2006;43:3–10
  63. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. 2000;95:2754–2759
  64. Ho VT, Weller E, Lee SJ, Alyea EP, Antin JH, Soiffer RJ. Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001;7:223–229
  65. Cutler C, Kim HT, Hochberg E, et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2004;10:328–336
  66. Bolwell B, Sobecks R, Pohlman B, et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant. 2004;34:621–625
  67. Copelan EA, Penza SL, Theil KS, et al. The influence of early transplantation, age, GVHD prevention regimen, and other factors on outcome of allogeneic transplantation for CML following BuCy. Bone Marrow Transplant. 2000;26:1037–1043
  68. Kumar S, Chen MG, Gastineau DA, et al. Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host disease. Bone Marrow Transplant. 2001;27:1133–1140
  69. Ross M, Schmidt GM, Niland JC, et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs-host disease: effect on chronic graft-vs.-host disease and long-term survival. Biol Blood Marrow Transplant. 1999;5:285–291
  70. Stem Cell Trialists’ Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol. 2005;23:5074–5087
  71. Burroughs L, Mielcarek M, Leisenring W, et al. Extending postgrafting cyclosporine decreases the risk of severe graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation. Transplantation. 2006;81:818–825
  72. Nieto Y, Patton N, Hawkins T, et al. Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation. Biol Blood Marrow Transplant. 2006;12:217–225

PII: S1083-8791(07)00194-2

doi: 10.1016/j.bbmt.2007.03.002

Biology of Blood and Marrow Transplantation
Volume 13, Issue 7 , Pages 790-805 , July 2007

Article Tools

* Image Usage & Resolution